Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE BENEFITS FOR THE PATIENT ASSOCIATED WITH THE TREATMENT OF PLAQUE PSORIASIS WITH APREMILAST AFTER OTHER SYSTEMIC TREATMENTS IN CONDITIONS OF CLINICAL PRACTICE IN SPAIN (APPROPRIATE Study)

Trial Profile

PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE BENEFITS FOR THE PATIENT ASSOCIATED WITH THE TREATMENT OF PLAQUE PSORIASIS WITH APREMILAST AFTER OTHER SYSTEMIC TREATMENTS IN CONDITIONS OF CLINICAL PRACTICE IN SPAIN (APPROPRIATE Study)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms APPROPIATE
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 26 Jul 2018 Last checked against ClinicalTrials.gov.
    • 18 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 31 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top